Ask about this productRelated genes to: Cdc2 antibody
- Gene:
- MCM4 NIH gene
- Name:
- minichromosome maintenance complex component 4
- Previous symbol:
- CDC21
- Synonyms:
- CDC54, hCdc21, P1-Cdc21, MGC33310
- Chromosome:
- 8q11.21
- Locus Type:
- gene with protein product
- Date approved:
- 1994-12-13
- Date modifiied:
- 2019-04-23
Related products to: Cdc2 antibody
Related articles to: Cdc2 antibody
- Chemoresistance is a major challenge in lung adenocarcinoma (LUAD) treatment and is associated with mitochondrial metabolism. Using publicly available LUAD transcriptome data, we established a five-gene prognostic signature (, , , , and ) for LUAD through differential gene expression profiling, univariate Cox analysis, and machine learning-based feature selection. Patients with LUAD were classified into a high-risk group (HRG) and a low-risk group (LRG) based on their risk scores. Enrichment analysis revealed significant differences between the HRG and LRG in multiple pathways related to metabolism and immunity. The immune microenvironment also differed significantly between the two groups, and the prognostic genes were correlated with infiltrating immune cells. A total of 110 compounds exhibited differential sensitivity across the groups. Molecular docking demonstrated a favorable binding affinity between the prognostic genes and the predicted drugs. Furthermore, knockdown significantly suppressed cancer cell proliferation in cell and animal models. In addition, knockdown markedly reduced cisplatin resistance by downregulating key regulators of the DNA replication and repair pathway, including and . These results provide insight into the molecular mechanisms underlying chemoresistance and identify putative therapeutic targets for LUAD treatment. - Source: PubMed
Publication date: 2026/03/27
Tan BinbinYang JinxuZhao XibaoLiu Shanshan - To investigate the expression and predictive value of minichromosome maintenance proteins MCM2, MCM4, and MCM10 in hepatocellular carcinoma (HCC) for postoperative recurrence, and to develop an integrated predictive model. - Source: PubMed
Publication date: 2026/03/21
He BinTang Ke - Multilocus pathogenic variants are increasingly recognized in neonates with complex phenotypes and have important implications for diagnosis and clinical management. Reporting such cases helps expand the phenotypic spectrum and improve clinical understanding of blended genetic disorders. - Source: PubMed
Publication date: 2026/01/04
Zhu KailaiYi YingShen YijingYang SufangZheng FangYang JinglinZhang HengWang Chuanguang - Solid pseudopapillary neoplasm (SPN) of the pancreas is a rare tumor with generally indolent behavior, and surgical resection yields a 5-year survival rate >95%. However, 5% to 10% of patients develop metastases, underscoring the need for reliable prognostic biomarkers to identify individuals at a higher metastatic risk and to optimize postoperative management. In this study, we performed data-independent acquisition mass spectrometry based proteomics profiling on resected primary tumors from 59 SPN patients to identify proteins differentially expressed between metastatic and nonmetastatic cases. A candidate protein, MCM4, was further examined for potential pathogenic functions in vitro. An independent multicenter cohort of 255 patients was subsequently analyzed for MCM4 positivity by immunohistochemistry. Prognostic performance for postoperative metastasis was evaluated using Kaplan-Meier analysis, Cox regression, and time-dependent receiver operating characteristic curves, with histopathological invasion defined as neural, vascular, or peripancreatic invasion. MCM4 protein was aberrantly upregulated in tumors from patients who developed metastasis, and functional assays demonstrated a proproliferative role of MCM4. In the validation cohort, MCM4-positive tumors (MCM4 index, >3%) exhibited a higher Ki-67 index (P = .0006). Patients with MCM4-positive tumors had a higher incidence of metastasis (20.6% vs 4.1%; P = .0019) and significantly shorter metastasis-free survival (MFS; log-rank P < .0001). In univariate Cox regression analysis, MCM4 positivity was significantly associated with reduced MFS (hazard ratio, 12.78; 95% CI, 3.01-54.31; P = .0006). In multivariate Cox regression analysis, MCM4 positivity remained an independent prognostic biomarker for shorter postoperative MFS after adjustment for histopathological invasion (hazard ratio, 11.55; 95% CI, 2.76-48.37; P = .0008). Time-dependent receiver operating characteristic analyses demonstrated that MCM4 positivity achieved area under the curves of 0.817 (95% CI, 0.763-0.864) at 3 years and 0.777 (95% CI, 0.720-0.828) at 5 years for postoperative metastasis assessment. Taken together, these findings identify MCM4 positivity as an independent prognostic biomarker for postoperative metastasis risk assessment in SPN. - Source: PubMed
Publication date: 2026/02/02
He RuizheLiu YuanhaoDun RuikangRen SiyuanTian WenminGao HuanyuShi YihongPan XuGe XinyangZhang JingyueChen YangWang XunChen YangWu JianhuiZhang RonghuaWang WenzeZhao YupeiPeng Junya - N-(1,3-dimethylbutyl)-N'-phenyl-p-phenylenediamine-quinone (6PPD-Q), a transformation product of tire rubber antioxidants, has been increasingly recognized as an emerging environmental contaminant with potential reproductive toxicity. Although growing evidence implicates 6PPD-Q exposure in male infertility, its role in specific pathological conditions such as sertoli cell-only syndrome (SCOS) in non-obstructive azoospermia (NOA) remains unclear. - Source: PubMed
Publication date: 2026/01/29
Jiang XiyaLu HedongOu GeZhang TaoXie LanxinZhou JiHou WenwenXu QingyangHu WeihuaZou WeiweiCao Yunxia